Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience

    loading  Checking for direct PDF access through Ovid


Telbivudine is a relatively novel oral nucleoside analogue with favourable efficacy and tolerability in treatment-naïve chronic hepatitis B virus (HBV) infection, but its data in kidney transplant recipients (KTRs) was lacking. The efficacy and tolerability of telbivudine in four treatment-naïve HBsAg-positive KTRs were reviewed (treatment duration 54 (36–72) months) HBV DNA declined from 2.6 × 105(7.8 × 103–1.5 × 107) copies/mL at baseline to 170 (0.0–3.2 × 104) copies/mL at 12 months, and became undetectable at 24 and 36 months (P = 0.060, 0.118 and 0.005 compared with baseline). Alanine aminotransferase levels dropped from 46.5 (30–48) IU/mL at baseline to 28 (13–45) IU/mL, 34.5 (15–71) IU/mL and 26 (12–41) IU/mL at 12, 24 and 36 months, respectively (P = 0.109, 0.715 and 0.068 compared with baseline). Serum creatinine level and estimated glomerular filtration rate (eGFR) remained stable after 36 months of treatment (P all > 0.05 compared with baseline). No virological breakthrough, cirrhosis or hepatocellular carcinoma occurred. Our pilot data suggests that telbivudine has favourable efficacy and renal safety profiles in HBsAg-positive KTRs.

Related Topics

    loading  Loading Related Articles